Intellia Therapeutics (NTLA) said Sunday that 10 patients with hereditary angioedema patients in a phase 1/2 study were attack-free and treatment-free for a median of nearly two years after a single dose of its Crispr-based potential therapy lonvoguran ziclumeran.
The genetic disease recurrent swelling and possible abdominal pain.
With up to three years of follow-up, patients in the study experienced a mean reduction of monthly attacks of 98% after the single dose, the company said.
A phase 3, randomized, double-blind, placebo-controlled trial is ongoing, the company said.
Intellia also said it expects to submit a biologics license application in 2026 to support its plans for a US launch in 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.